AtriCure (ATRC) Cash & Equivalents (2010 - 2026)

AtriCure (ATRC) has 17 years of Cash & Equivalents data on file, last reported at $146.2 million in Q1 2026.

• Quarterly Cash & Equivalents rose 46.33% year-over-year to $146.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146.2 million (up 46.33% YoY) and the FY2025 annual result came in at $167.4 million, up 36.43% from the prior year.
• Cash & Equivalents eased to $146.2 million in Q1 2026 per ATRC's latest filing, from $167.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $167.4 million in Q4 2025 and bottomed at $28.1 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $84.3 million (2023), against an average of $94.3 million.
• The widest annual swing landed in 2022, when Cash & Equivalents sank 67.04%; it then surged 174.83% in 2023.
• Tracing ATRC's Cash & Equivalents over 5 years: stood at $58.1 million in 2022, then soared by 45.11% to $84.3 million in 2023, then soared by 45.56% to $122.7 million in 2024, then soared by 36.43% to $167.4 million in 2025, then declined by 12.7% to $146.2 million in 2026.
• Per Business Quant, the three latest ATRC Cash & Equivalents figures stand at $146.2 million (Q1 2026), $167.4 million (Q4 2025), and $147.9 million (Q3 2025).

Peer Comparison